Pregnancy is a time of immense change, hope, and responsibility—but for individuals managing opioid use disorder (OUD), it can also be a time of heightened risk. One critical concern is opioid withdrawal, which can pose serious threats to both mother and baby if not properly managed.
Recent research highlights the life-saving importance of medication-assisted treatment (MAT) during pregnancy. This includes options like buprenorphine and methadone, which help stabilize opioid use and reduce the risk of dangerous withdrawal symptoms.
Let’s explore why withdrawal during pregnancy is dangerous and how MAT offers a safe and effective path forward.
Why Is Opioid Withdrawal Dangerous During Pregnancy?
Opioid withdrawal isn’t just uncomfortable—it’s physically and emotionally taxing, and for pregnant individuals, it comes with added risks.
1. Maternal Risks
When a pregnant individual suddenly stops using opioids, withdrawal symptoms can include:
- Severe nausea and vomiting.
- Dehydration.
- Increased heart rate and blood pressure.
- Anxiety and depression.
These symptoms can strain the body, potentially leading to complications like preterm labor or miscarriage.
2. Fetal Risks
Withdrawal doesn’t just affect the mother—it also impacts the developing baby. Without access to opioids, the fetus may experience:
- Reduced oxygen levels due to maternal stress.
- Fetal distress.
- Growth restrictions or low birth weight.
In severe cases, untreated withdrawal can lead to stillbirth.
How MAT Prevents Withdrawal Risks
MAT, including buprenorphine and methadone, is the gold standard for treating OUD during pregnancy. Here’s why:
1. Stabilizes Opioid Levels
MAT prevents the extreme highs and lows of opioid use. By stabilizing opioid levels in the bloodstream, it reduces withdrawal symptoms and protects the developing baby.
2. Improves Prenatal Care
MAT increases the likelihood that patients will stay in treatment and receive consistent prenatal care. This leads to better outcomes for both mother and baby.
3. Reduces Neonatal Abstinence Syndrome (NAS)
Research shows that MAT can lower the risk of NAS—a condition where newborns experience withdrawal after birth. Babies exposed to buprenorphine during pregnancy, for example, often have shorter hospital stays and milder symptoms than those exposed to methadone.
Did you know? A recent study found that buprenorphine is associated with an 18% lower risk of congenital malformations compared to methadone. Learn more here.
What the Research Says About MAT During Pregnancy
The landmark study led by Dr. Elizabeth Suarez analyzed over 13,000 pregnancies involving buprenorphine or methadone. Key findings included:
- Reduced malformations with buprenorphine: 50.9 per 1,000 pregnancies versus 60.6 per 1,000 with methadone.
- MAT is significantly safer than untreated OUD, which increases the risks of relapse, overdose, and inadequate prenatal care.
These findings underscore the importance of evidence-based treatment during pregnancy.
How to Get Help with MAT
Accessing MAT during pregnancy can feel overwhelming, but there are resources to help.
1. Talk to Your Doctor
Your healthcare provider can guide you toward the best treatment option for your needs, whether it’s buprenorphine, methadone, or other support services.
2. Use Trusted Telemedicine Services
Platforms like QuickMD make it easier than ever to access MAT and buprenorphine prescriptions from the comfort of home. With licensed providers and HIPAA-compliant technology, QuickMD ensures confidential, compassionate care.
FAQs About Opioid Withdrawal in Pregnancy
Can I stop using opioids during pregnancy without treatment?
It’s not recommended. Sudden withdrawal can harm both you and your baby. Always seek medical guidance before stopping opioid use.
Is MAT safe for my baby?
Yes, MAT is proven to improve pregnancy outcomes and reduce risks compared to untreated OUD.
How can I start MAT during pregnancy?
Contact your healthcare provider or explore telemedicine options like QuickMD for fast, confidential access to care.
Compassionate Care for Every Step
If you or a loved one is navigating opioid use during pregnancy, help is available. MAT offers a lifeline, reducing risks and improving outcomes for both mother and baby.
Ready to take the first step? Schedule a confidential consultation with QuickMD today and access the care you need to protect your health and your baby’s future.
If you or someone you know is struggling with opioid use during pregnancy, resources are available. Visit SAMHSA.gov or call their helpline at 1-800-662-HELP (4357) for confidential support and treatment options.
References: Suarez EA, Bateman BT, Straub L, et al. First Trimester Use of Buprenorphine or Methadone and the Risk of Congenital Malformations. JAMA Intern Med. 2024;184(3):242–251.
